CRISPR gene editing therapy show promise in Hereditary angioedema
Print
Email
CRISPR has been proven to treat blood diseases using an ex vivo technique in which cells from a patient are taken, modified in a lab, and afterward released to the body. An in vivo technique for blindness problems, in which the gene editor is administered into the eyes, is also demonstrating promising results. However, targeting CRISPR to target organs or cells within the body via intravenous administration is more difficult.
Intellia and partner Regeneron announced last year in a landmark research that an in vivo CRISPR medicine stopped the buildup of hepatic proteins that can induce nerve pain, numbness, and cardiac difficulties in people with a rare hereditary illness called transthyretin (ATTR) amyloidosis. Although the protein knockdown looks to be long-lasting, the company has yet to announce if the patient's symptoms improved. According to Intellia, the benefits of the experiment in hereditary angioedema became apparent quickly.
A rare genetic illness known as hereditary angioedema (HAE) causes severe, sporadic, inflammatory assaults such as rapid swelling in a variety of body organs and tissues. These attacks can be excruciatingly painful, incapacitating, and even fatal. One in 50,000 persons is thought to be afflicted by HAE, and current medications frequently involve lifelong regimens that may require chronic intravenous (IV), subcutaneous (SC), or daily oral dosing to maintain ongoing pathway suppression for disease control. Despite persistent management, breakthrough attacks still happen. The prevention of HAE attacks can be managed with the help of the clinically proven method of kallikrein inhibition.
- Intellia Therapeutics now has a few more pieces of evidence suggesting that its second gene-editing candidate may offer a therapeutic cure for hereditary angioedema (HAE).
- NTLA-2002 is Intellia's second CRISPR therapeutic candidate under research and will be infused intravenously to modify disease-causing genes within the human body in a single dose. It is the first drug being tested in clinical trials with the potential to continually lower kallikrein activity and prevent attacks in persons with hereditary angioedema. It is based on CRISPR/Cas9 technology (HAE). The kallikrein B1 (KLKB1) gene, which codes for prekallikrein, the kallikrein precursor protein, is intended to be inactivated by NTLA-2002. NTLA-2002 lowered mean plasma kallikrein levels at different doses according to preliminary findings from a phase 1/2 research released by the company in September.
- HAE medications that have been approved strive to stop or slow attacks by inhibiting this process. However, Intellia is expecting that NTLA-2002 would offer a one-time solution that will permanently lower kallikrein activity and so stop attacks.
- Despite the limited size of the data sample, Intellia is now announcing that at the most recent follow-up, every patient in the 25 mg and 75 mg groups had an uninterrupted period without an incident. After one dose, the first three patients experienced no attacks for 5.5 months to 10.6 months on average.
- According to Intellia, the most recent data demonstrates a persistent response. Although genetic manipulation has been a much-discussed new technique, it is still unclear if the alteration is permanent. By providing persistent responses like these, Intellia, one of the top gene editing businesses with data available, hopes to provide answers to such queries. This candidate's profound and consistent protein decrease following a single dose, according to Intellia, is now seen twice, supporting the company's CRISPR platform. The majority of adverse effects associated with NTLA-2002 were modest, including infusion-related responses that subsided within a day, and it was usually well tolerated. No dose-limiting toxicities have been reported by patients, and no grade 3 or more side effects have been observed.